Onfekafusp alfa not checked

Philogen S.p.A. · L19TNF · L19TNF and CCNU

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
6 active
13 in total · 7 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“L19TNF, 13 μg/kg, on Day 1, 3, and 5 of every 21-day cycle for a maximum of 6 induction cycles. Patients experiencing apparent or real benefit with minimal or acceptable toxicity from the first 6 cycles of treatment, can receive, at investigator's discretion, maintenance treatment of 13 μg/kg, on Day 1 every 21-day”In the company’s words, NCT04733183 on ClinicalTrials.gov
Tested for
Glioblastoma (2 trials), Soft Tissue Sarcoma, Melanoma Stage III, Melanoma Stage IV, Glioma, Locally Advanced Basal Cell Carcinoma
Main trialPhase 2
“Open label, randomized, controlled phase II study preceded by a safety run-in part in subjects with advanced or metastatic soft-tissue sarcoma.”In the company’s words, NCT04733183 on ClinicalTrials.gov
Other names
L19TNF · onfekafusp alpha · L19TNF and CCNU · L19TNF and CCNU in recurrent astrocytoma · L19TNF and TMZ · L19TNF and TMZ in recurrent astrocytoma

Other drugs for Glioblastoma

All 93 drugs for Glioblastoma

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials13

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting Dec 2025 Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
Phase 2Active, not recruiting Jun 2026 A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
Phase 2Recruiting Jul 2028 Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
Phase 2Not yet recruiting 30 Jan 2029 A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma
Phase 2Recruiting Feb 2031 L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Phase 1/2Recruiting Oct 2026 Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
Phase 3Unknown 31 Dec 2025 A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Phase 2Unknown Dec 2024 Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)
Phase 1/2Completed 27 Jun 2023 Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse
Phase 1/2Unknown Mar 2025 A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression
Phase 1Completed 25 Jan 2018 L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours
Phase 1Unknown Dec 2024 Dose Finding Study of L19TNF and Doxorubicin in Patients With STS
Phase 1Withdrawn 31 Dec 2024 Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Onfekafusp alfa

Following is part of Solo: you see every change to Onfekafusp alfa the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in